19.96
+0.04(+0.20%)
Currency In USD
| Previous Close | 19.92 |
| Open | 19.41 |
| Day High | 20.15 |
| Day Low | 19.26 |
| 52-Week High | 30.03 |
| 52-Week Low | 13.3 |
| Volume | 610,837 |
| Average Volume | 478,806 |
| Market Cap | 1.18B |
| PE | -10.03 |
| EPS | -1.99 |
| Moving Average 50 Days | 20.35 |
| Moving Average 200 Days | 20.69 |
| Change | 0.04 |
If you invested $1000 in Enliven Therapeutics, Inc. (ELVN) since IPO date, it would be worth $332.67 as of September 13, 2025 at a share price of $19.96. Whereas If you bought $1000 worth of Enliven Therapeutics, Inc. (ELVN) shares 3 years ago, it would be worth $2,278.54 as of September 13, 2025 at a share price of $19.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
GlobeNewswire Inc.
Sep 28, 2024 1:35 PM GMT
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phas
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
GlobeNewswire Inc.
Sep 18, 2024 8:05 PM GMT
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inh